In HCC murine models, combined Radiotherapy and anti-PD-L1 therapy enhanced survival and tumor control versus monotherapies, with Radiotherapy -induced PD-L1 upregulation via IFN-gamma/STAT3 potentially boosting immunotherapy (132). The gene discussed is IFNG; the disease is hepatocellular carcinoma.